Murad Husain

Murad Husain has extensive experience in global regulatory affairs. Murad began their career at Ben Venue Laboratories as a Manager of Regulatory Affairs, where they worked from 1991 to 1994. Murad then joined Astra USA as an Associate Director of Regulatory Affairs, focusing on the development of regulatory strategies and the submission of New Drug Applications. After Astra merged with Astra-Merck, they gained approval for the herpes simplex indication for Foscavir. Murad then joined EMD Serono as a Director of Regulatory Affairs for a brief period in 1999. In 2000, they became a Director and Global Regulatory Leader at Hoffman-La Roche, where they gained approvals for Xeloda for the treatment of colorectal cancer and metastatic breast cancer. Murad later joined Pfizer Inc as a Worldwide Director of Regulatory Strategy, where they were responsible for global regulatory leadership for Celebrex in oncology and Geodon in psychiatry. Subsequently, they joined Savient Pharmaceuticals as a VP of Regulatory Affairs, developing regulatory strategies for the registration of KRYSTEXXA for the treatment of chronic gout. Murad gained approval for KRYSTEXXA in the US and submitted a Marketing Authorization Application to the EMA. In 2012, they joined PGS PharmaServ as a Managing Partner before moving to PTC Therapeutics, Inc. as a Vice President of Global Regulatory Affairs. There, they led the Regulatory team in gaining CHMP positive opinion for the Marketing Authorization approval of a gene therapy and developed global regulatory strategies for various drugs and gene therapies in rare diseases. Murad also built highly driven regulatory professional and scientific writing teams worldwide. Overall, Murad Husain has a strong background in regulatory affairs and has achieved significant approvals throughout their career.

Murad Husain completed their M.Pharm. in Pharmacy from the University of Dhaka in 1981. Murad then pursued an MS degree in Pharmaceutical Marketing from St. John's University from 1983 to 1985.